The effectiveness of second- and-third-line biologics in perianal Crohn's disease-a multicenter propensity score-matched study.
Shani U, State M, Mateescu RB, Davidoiu AM, Negreanu L, Silva I, Magro F, Lees CW, Plevris N, Roblin X, Castellet-Farrús S, Gonzalez Lama Y, Wang S, Abad C, Imperatore N, Lukas M, Vojtechova G, Ukashi O, Ben-Horin S, Nancey S, Savarino E, Stawczyk-Eder K, Eder P, Toskas A, Kamperidis N, Arebi N, Farkas B, Farkas K, Pipek B, Falt P, Karmiris K, Nikolaou P, Krznaric Z, Brinar M, Hoentjen F, van Lierop L, Barreiro-de Acosta M, Zaborowska M, Zagorowicz E, Pugliese D, Cuccia G, Truyens M, Kopylov U.
Shani U, et al. Among authors: imperatore n.
J Crohns Colitis. 2025 Jun 4;19(6):jjaf099. doi: 10.1093/ecco-jcc/jjaf099.
J Crohns Colitis. 2025.
PMID: 40490896